RxDoctor Payments Data

Stephanie Dondero, DO

Rheumatology · Armonk, NYNPI 1578978656

Payments from drug & device makers

$2,165in general payments, 2019–2025

Across 70 payments — averaging $30.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$835
  • Amgen$347
  • Novartis$250
  • Aurinia Pharma U.S., Inc.$247
  • AstraZeneca$230
  • Pfizer$155
  • plus $101 from 2 others

What the payments were for

  • Food & beverage$2,07796%
  • Education$874%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie14$835
Amgen13$347
Novartis14$250
Aurinia Pharma U.S., Inc.2$247
AstraZeneca6$230
Pfizer19$155
Johnson & Johnson1$80
Lilly USA, LLC1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,165 in reported general payments places this provider in the 50th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$94,856
Medicare patients
236
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab95$885,591
RinvoqUpadacitinib82$770,031
Enbrel SureclickEtanercept60$527,918
Taltz AutoinjectorIxekizumab49$436,691
Cosentyx Sensoready (2 Pens)Secukinumab34$392,605
Orencia ClickjectAbatacept50$271,212
Cosentyx Sensoready PenSecukinumab25$250,896
OtezlaApremilast36$231,540
Xeljanz XrTofacitinib Citrate36$230,537
Actemra ActpenTocilizumab35$61,258
OrenciaAbatacept/Maltose11$51,909
ProliaDenosumab13$22,503
Hydroxychloroquine Sulfate468$15,991
MethotrexateMethotrexate Sodium336$9,241
Leflunomide102$6,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$835$770,03182 claims
AmgenOtezla, Prolia$347$254,04349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 541 rheumatology providers in New York.

Other rheumatology in Armonk

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →